Research Discovery: A Common Virus, A Vaccine, and A Potential Breakthrough for Pancreatic Cancer

Mar 13 3:22pm | Jasmine Souers | @jasminesouers

Pancreatic cancer is one of the hardest cancers to detect and treat. Doctors have known for a long time that most pancreatic cancers have changes in a gene called KRAS. However, many people develop these gene changes as they get older and never develop cancer. So why do some people go on to get pancreatic cancer while others do not?

Recent research suggests that a common viral infection may help trigger cancer in people who already have these early genetic changes. The studies also suggest that vaccination against this virus may help prevent cancer progression—at least in early laboratory studies.

What It Is

Researchers focused on a virus called Coxsackievirus B3 (CVB3). This virus is very common, and most people are exposed to it at some point in their lives. For most people, it causes mild symptoms or no symptoms at all. However, CVB3 can infect the pancreas and cause inflammation. Researchers wanted to know:

If someone already has early pancreatic cell changes linked to cancer, could this virus push those cells toward cancer?

If so, could a vaccine stop that from happening?

Two recent studies, published in Nature Communications (2024) and JCI Insight (2025), explored these questions using laboratory and animal models.

How It Works

Step 1: A Genetic Risk

Most pancreatic cancers are a type called pancreatic ductal adenocarcinoma. Almost all of these cancers involve changes in the KRAS gene. On its own, a KRAS mutation is usually not enough to cause cancer.

Step 2: A Viral “Second Hit”

The researchers found that pancreatic cells with KRAS mutations produce large amounts of a protein that acts like a doorway, allowing CVB3 to enter the cells more easily.

When the virus infects these already‑vulnerable cells, several harmful changes occur:

Long‑lasting inflammation in the pancreas

Build‑up of immune cells that can actually help cancer grow

Formation of scar‑like tissue

Breakdown of the body’s natural defenses that normally stop damaged cells from becoming cancer

In mice with KRAS mutations, even one CVB3 infection greatly sped up the development of pancreatic cancer. Importantly, mice without KRAS mutations did not develop cancer after infection. This shows that both the genetic risk and the viral infection were needed.

Key Findings

Across both studies, researchers found:

Signs of CVB3 infection in about half of the human pancreatic cancer samples studied

High levels of the virus “entry doorway” protein in most pancreatic tumors

In genetically at‑risk mice, CVB3 infection led to:

- More inflammation

- More cancer‑promoting immune cells

- More scarring

- Faster progression toward cancer

The Breakthrough: A Vaccine

In the 2025 study, researchers tested a vaccine made from harmless pieces of the CVB3 virus.

Mice with KRAS mutations were vaccinated before being exposed to the virus. Compared with unvaccinated mice, the vaccinated mice:

Developed strong antibodies against CVB3

Had far fewer infected pancreatic cells

Showed much less inflammation and scarring

Stayed in early, low‑risk stages instead of progressing toward cancer

This was the first strong evidence that vaccination could block virus‑driven cancer progression, at least in animal studies.

Why This Matters

Cancer Is Not Just About Genes

These findings suggest that pancreatic cancer may develop through a combination of genetic risk and environmental factors, such as viral infections. This helps explain why only some people with KRAS gene changes go on to develop cancer.

Prevention May Be Possible

If future studies confirm these results in people, preventing certain viral infections could lower cancer risk in those who are genetically vulnerable. In the future, vaccines might: